Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 03-28-2024 | 12-31-2023 | 10-K | |
| 2 | 11-09-2023 | 09-30-2023 | 10-Q | |
| 3 | 08-14-2023 | 06-30-2023 | 10-Q | |
| 4 | 06-15-2023 | 03-31-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $28 price target.
Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.99) by 2...
Wells Fargo analyst Derek Archila maintains Acelyrin (NASDAQ:SLRN) with a Equal-Weight and raises the price target from $11 ...
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated wit...
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $30 price target.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $30 price target.
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high st...
Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle end...
